Glimepirid Teva

Glimepirid Teva is a prescription oral medication that contains the active ingredient glimepiride, a sulfonylurea used to improve blood glucose control in adults with type 2 diabetes mellitus. The product is marketed in the European Union and is supplied in tablet form; specific strength and dosage form details are not disclosed in the available summary. It is intended for management and should be taken as directed by a healthcare professional.

Glimepirid Teva is indicated for the oral treatment of type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient to achieve glycemic targets.

- Improves fasting and post‑prandial blood glucose levels. - Can be used as monotherapy in patients newly diagnosed with type 2 diabetes. - May be combined with metformin or other oral antidiabetic agents when additional glucose lowering is needed. - Suitable for adults who have adequate pancreatic beta‑cell function. - Helps reduce HbA1c when taken consistently as part of a comprehensive diabetes management plan.

The safety profile of glimepiride includes a range of adverse effects that vary in frequency and severity.

Common: - Low blood sugar (hypoglycemia), especially when meals are skipped. - Weight gain. - Nausea or gastrointestinal discomfort. - Headache. - Dizziness.

Serious: - Severe hypoglycemia leading to loss of consciousness. - Allergic reactions such as rash, itching, or swelling. - Blood cell abnormalities (e.g., leukopenia, thrombocytopenia). - Liver function abnormalities. - Cardiovascular events in patients with pre‑existing heart disease.

Before initiating Glimepirid Teva, healthcare providers should evaluate several clinical factors to minimize risks.

- Assess renal and hepatic function; dose adjustments may be required in impairment. - Verify that the patient has sufficient endogenous insulin production. - Caution in elderly patients due to increased susceptibility to hypoglycemia. - Review history of cardiovascular disease, as sulfonylureas may affect cardiac outcomes. - Avoid use during pregnancy and lactation unless benefits outweigh risks. - Monitor for signs of allergic reactions during the first weeks of therapy. - Educate patients on recognizing and managing hypoglycemia.

Glimepirid Teva can interact with other medicines, altering its glucose‑lowering effect or increasing the risk of adverse events.

Avoid: - Concurrent use with other sulfonylureas or meglitinides, which can cause additive hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that may raise glimepiride plasma levels. - High‑dose salicylates or NSAIDs that can potentiate hypoglycemic episodes.

Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms. - Thiazide diuretics, which can affect blood glucose control. - Antidepressants such as SSRIs, which have been reported to influence glycemic balance.